Outlook Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Outlook Therapeutics reported net losses of $62.4M (FY2025) and $75.4M (FY2024). LYTENAVA generated only $1.4M revenue in FY2025 from Germany/UK launches; US commercial launch not yet commenced (FDA approval July 2026). Cash position of $7.7M (March 31, 2026) plus $4.2M (April offering) and $4.9M (May offering) estimated sufficient only through September 2026. Company carries $19.8M debt (Atlas note, 9.5% minimum, 7.5% exit fee, redeemable starting Sept 2026). Substantial doubt about going concern. Company is entirely dependent on LYTENAVA commercialization success with limited operating history and no prior drug commercialization experience.
Why this rating
Going concern doubt + 9-month cash runway + $1.4M revenue vs $62M losses = existential threat to $26.9M market cap company. Highly significant.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.